Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn’s and Colitis Foundation’s IBD Innovate Conference
December 4, 2019IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune…Immunic, Inc. to Participate in Investor and Scientific Conferences in December
November 25, 2019NEW YORK, November 25, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for…Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
November 19, 2019NEW YORK, November 19, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
November 7, 2019NEW YORK, November 7, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. to Participate in Industry and Investor Conferences in November
November 5, 2019SAN DIEGO, November 5, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
October 15, 2019SAN DIEGO, October 15, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
October 10, 2019– Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 – SAN DIEGO, October 10,…Immunic, Inc. to Participate in Investor and Scientific Conferences in October
September 30, 2019SAN DIEGO, September 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for…Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
September 18, 2019SAN DIEGO, September 18, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment…Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019
September 11, 2019Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis SAN…
